Merck & Co., Inc. 13F holdings
Merck & Co., Inc. reported 13 positions with a total reported value of $526.4M as of 2026-06-30, in its 13F for Q2 2026, filed 2026-08-07. Top holdings by reported value: PSNL PERSONALIS INC (35.8%), MRNA MODERNA INC (30.7%), KYMR KYMERA THERAPEUTICS INC (16.8%), AKTS AKTIS ONCOLOGY INC (5.8%), EIKN EIKON THERAPEUTICS INC (4.1%). Against 2026-03-31 it opened 1 new position and exited 2. Next 13F due by 2026-11-14, the legal deadline 45 days after the quarter ending 2026-09-30.
Email me when Merck & Co., Inc. files its 13F
A free account follows up to 10 funds. New 13F filings arrive in your daily or weekly digest. No password and no card.
Top holdings
13 largest of 13 positions · reported value as of 2026-06-30
| Holding | Shares | Reported value | % of portfolio |
|---|---|---|---|
| PSNL PERSONALIS INC | 14,044,943 | $188.2M | 35.8% |
| MRNA MODERNA INC | 2,308,190 | $161.6M | 30.7% |
| KYMR KYMERA THERAPEUTICS INC | 772,165 | $88.5M | 16.8% |
| AKTS AKTIS ONCOLOGY INC | 952,844 | $30.7M | 5.8% |
| EIKN EIKON THERAPEUTICS INC | 1,666,666 | $21.7M | 4.1% |
| TRDA ENTRADA THERAPEUTICS INC | 1,739,768 | $12.8M | 2.4% |
| STRO SUTRO BIOPHARMA INC | 272,351 | $9.0M | 1.7% |
| ALEC ALECTOR INC | 3,545,719 | $7.1M | 1.4% |
| EVAX EVAXION BIOTECH A/S | 1,214,126 | $3.8M | 0.7% |
| VIRIDIAN THERAPEUTICS INC | 93,414 | $1.7M | 0.3% |
| XLO XILIO THERAPEUTICS INC | 105,982 | $1.0M | 0.2% |
| HURA TUHURA BIOSCIENCES INC | 19,445 | $45.5K | <0.1% |
| NEUP NEUPHORIA THERAPEUTICS INC | 10,027 | $43.8K | <0.1% |
SEC FORM 13F · Q2 2026 · VALUES AS REPORTED, NOT PRICES
New positions this quarter
Held at 2026-06-30, not at 2026-03-31 · 1 in all · reported value as of 2026-06-30
| Holding | Shares | Reported value | % of portfolio |
|---|---|---|---|
| EVAX EVAXION BIOTECH A/S | 1,214,126 | $3.8M | 0.7% |
Sold out
Held at 2026-03-31, gone by 2026-06-30 · 2 in all · reported value as of 2026-03-31
| Holding | Shares 2026-03-31 | Reported value | % of portfolio then |
|---|---|---|---|
| EVAXION BIOTECH A/S | 1,214,126 | $4.5M | 1.3% |
| CARISMA THERAPEUTICS INC | 1,473,240 | $47.9K | <0.1% |
Biggest increases and decreases
Positions held at both quarter ends, by change in shares · reported value as of 2026-06-30
Increases
No position was increased.
Decreases
No position was decreased.
CIK 310158 · 13F FILINGS ON EDGAR · INFORMATIONAL ONLY
